Investigating the use of panobinostat in multiple myeloma
PANORAMA (PANobinostat ORAl in Multiple myelomA) is a group of Novartis-sponsored clinical trials investigating the use of panobinostat in combination with other drugs that are used to treat multiple myeloma.
Treatment for multiple myeloma has been focused on 2 types of drugs: proteasome inhibitors (including bortezomib) and immunomodulatory drugs (including lenalidomide or pomalidomide). Panobinostat is in a class of drugs called deacetylase inhibitors, which act on the enzymes that may have a key role in one of the pathways myeloma cells use to survive.
Novartis is now recruiting patients who have relapsed or relapsed/refractory multiple myeloma to participate in a clinical trial. By participating in this trial, you may receive panobinostat in combination with other drugs that are commonly used to treat multiple myeloma. All study participants will receive care from a specialized team of health care professionals at a clinical trial site. Please take your time learning about this trial.
As with all clinical trials, you have the right to leave the study at any time, for any reason.